Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Sparad:
| Huvudskapare: | , |
|---|---|
| Materialtyp: | Bok |
| Publicerad: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| Ämnen: | |
| Länkar: | Connect to this object online. |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signum: |
A1234.567 |
|---|---|
| Exemplar 1 | Tillgänglig |